SAMIA
A Hybrid Clinical Decision Support System to Accelerate the Classification of MCAS
In partnership with Alfasigma, we developed Project SAMIA
A Clinical Decision Support System (CDSS) that simplifies the complex classification of Mast Cell Activation Syndrome (MCAS). Scientific literature consistently shows that diagnostic delays are substantial. In MCAS, the average delay ranges from 3 to 8 years depending on the cohort and healthcare setting and can exceed two decades in cases limited to skin involvement or with atypical symptoms (Tse et al 2024, Ungerstedt et al 2022). Reducing these delays requires better training of dermatologists, allergists, hematologists and primary care physicians, clear referral pathways to specialized centers and wider access to tests that measure mast cell mediators.
SAMIA’s innovative hybrid system provides clinicians with two core features: a guided platform to systematically apply international classificatory criteria and a specialized AI assistant for instant clinical support. Designed strictly as an assistive tool, it improves classification accuracy for suspected cases. The system is built on a secure, GDPR-compliant architecture that guarantees complete data anonymization, ensuring both technical feasibility and ethical integrity. This project exemplifies our science-based approach to creating practical solutions that deliver clear value to patients, healthcare professionals and the wider healthcare system.